Story

US Prescription Volume Rose 1.9% in July, Driven by Specialty and GLP-1 Drugs, Evercore Says

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
US Prescription Volume Rose 1.9% in July, Driven by Specialty and GLP-1 Drugs, Evercore Says
Text size
Background

Total prescription volumes in the United States rose 1.9% year-over-year in July, reaching 575 million prescriptions, according to a new analysis released by Evercore. The data also showed a 1.6% increase compared to the previous month, indicating sustained demand across the pharmaceutical sector.

Specialty and Branded Drugs Lead Growth

The July increase was primarily driven by strong performance in higher-value categories. According to Evercore's report, key growth segments included:

  • Specialty prescriptions: Jumped 8.5% year-over-year.
  • Branded prescriptions: Increased 3.7% from the same period last year.
  • Generic prescriptions: Climbed a more modest 1.6%.

Mail order services continued to gain traction, with volumes increasing 8.4% year-over-year to capture approximately 13.0% of the total market share. However, the report noted a deceleration in the broader medical specialty market, with sales growth slowing to approximately 12% year-over-year in June, down from a peak of 24% in July 2025.

GLP-1 Demand Surges Amid New Medicare Program

Sample IUX Markets – In-articleAd

Prescriptions for GLP-1 drugs, a class that includes popular weight-loss and diabetes treatments, reached approximately 12.0 million in July. This represents a 29% year-over-year increase and a 4% rise from June, with the category now accounting for about 2.1% of all prescriptions.

The launch of the Medicare GLP-1 Bridge program on July 1, 2026, appears to have boosted demand. The program sets a $50 monthly copay for beneficiaries on drugs like Wegovy, Zepbound, and Foundayo. Combined weekly new prescriptions for these three drugs averaged 780,000 in the last three weeks of July, an 11.6% increase from the 698,000 average in June. The share of cash-pay patients for GLP-1s also rose to approximately 18%, up from roughly 5% a year prior.

Inflation and Market Context

In other market indicators, generic drug deflation eased slightly to 7.1% in June, compared to 7.8% in May, Evercore reported. Inflation for branded drugs remained flat during the same period. The slowing growth in oncology sales, which grew approximately 11% year-over-year versus a 25% peak, suggests a moderating trend in some high-growth specialty areas.

Read next

More on Stocks
Back to latest news

LATEST